Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200833 | 1.00 | ACE (0.48) | ACEHSD17B10SMN1; SMN2USP2PREP | |
| SCHEMBL201910 | 1.00 | ACE (0.48) | ACEHSD17B10SMN1; SMN2USP2PREP | |
| SCHEMBL17031886 | 0.87 | USP2 (0.38) | ACEHSD17B10SMN1; SMN2USP2PREP | |
| SCHEMBL16790938 | 0.87 | USP2 (0.38) | ACEHSD17B10SMN1; SMN2USP2PREP | |
| SCHEMBL13005067 | 0.85 | USP2 (0.37) | ACEHSD17B10SMN1; SMN2USP2PREP | |
| SCHEMBL201146 | 0.84 | NR1H2 (0.37) | HSD17B10SMN1; SMN2USP2CHRM2CHRM1 | |
| SCHEMBL201569 | 0.84 | NR1H2 (0.37) | HSD17B10SMN1; SMN2USP2CHRM2CHRM1 | |
| SCHEMBL22511349 | 0.84 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2USP2PREPCHRM2 | |
| SCHEMBL201144 | 0.84 | NR1H2 (0.37) | HSD17B10SMN1; SMN2USP2CHRM2CHRM1 | |
| SCHEMBL14209871 | 0.79 | USP2 (0.40) | HSD17B10SMN1; SMN2USP2PREPRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101407502-B | N-(t-butoxy carbonyl ) timonacic compounds, and preparation and use thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2010-12-22 | — | — | CN | claimed |
| CN-101407502-A | N-(t-butoxy carbonyl ) timonacic compounds, and preparation and use thereof | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2009-04-15 | — | — | CN | claimed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2024215870-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POLYMERASE THETA AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-118480082-A | Metal ion-mediated thiazolidine deprotection and aldehyde group formation protein site-directed chemical modification method | 浙江工业大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3688007-B1 | BIOCONJUGATION OF POLYPEPTIDES | UNIV YORK (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-11897917-B2 | Bioconjugation of polypeptides | THE UNIVERSITY OF YORK (GB) | 2024-02-13 | — | — | US | disclosed |
| WO-2022073003-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | NEW YORK BLOOD CENTER, INC (US) | 2022-04-07 | — | — | WO | disclosed |
| CN-106946848-B | Derivatives of 1-phenyl-2-pyridylalkylalcohols as phosphodiesterase inhibitors | 奇斯药制品公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113480596-A | Compound for regulating NMDA receptor activity, pharmaceutical composition and application thereof | 北京广为医药科技有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-110003309-B | Compounds that modulate NMDA receptor activity, pharmaceutical compositions and uses thereof | 北京广为医药科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-1314883-A | Amino acid derivative and drug containing the same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2001-09-26 | — | — | CN | disclosed |
| EP-1090912-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-04-11 | — | — | EP | disclosed |
| CN-1264385-A | Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and compositions containing same | SOD CONSEILS RECH APPLIC (FR) | 2000-08-23 | — | — | CN | disclosed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | disclosed |
| EP-0677060-A1 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994015958-A2 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1994-07-21 | — | — | WO | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0175363-B1 | 4,5-DIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4816454-A | CARDIOVASCULAR DISORDERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1989-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | ACE 4608/4885HSD17B10 1989/4885SMN1; SMN2 4700/4885 |
| US-11897917-B2 | Bioconjugation of polypeptides | PTMS, EPCAM, IAPP | ACE 369/4885HSD17B10 2256/4885SMN1; SMN2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.